Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score 2.00
- Grade Outperform
- Symbol (VECT)
- Company VectivBio Holding AG
- Price $16.87
- Changes Percentage (0.12%)
- Change $0.02
- Day Low $16.80
- Day High $16.88
- Year High $16.98
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/18/2023
- Fiscal Year End N/A
- Average Stock Price Target $18.00
- High Stock Price Target $18.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.10
- Trailing P/E Ratio -8.0333333333333
- Forward P/E Ratio -8.0333333333333
- P/E Growth -8.0333333333333
- Net Income $-93,735,000
Income Statement
Quarterly
Annual
Latest News of VECT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma, Inc. stock declined due to Phase 1b study results on NXP800 for ovarian cancer. Efficacy was observed with some patients showing tumor responses. The company plans to increase dosage ...
By Yahoo! Finance | 1 week ago -
Vection Technologies Full Year 2024 Earnings: AU$0.009 loss per share (vs AU$0.01 loss in FY 2023)
Vection Technologies' shares have increased by 13% in the past week. Before making decisions, be aware of the 4 warning signs identified for the company. Simply Wall St's article offers general analys...
By Yahoo! Finance | 1 month ago -
Vector Group Ltd. (VGR) Stock Price, News, Quote & History
Vector Group Ltd. manufactures and sells cigarettes in the US, operating in Tobacco and Real Estate segments. It produces various cigarette brands and invests in real estate properties. Founded in 187...
By Yahoo! Finance | 3 months ago
